University of PittsburghUniversity of Pittsburgh
Startups
TechnologiesStartupsExpress LicensesCollectionsChat with AI
Sign in
University of Pittsburgh

Ikshana Therapeutics, Inc.

OverviewRequest InfoMore Like ThisExpress Licenses

Sector

Therapeutics

Therapeutic Areas

Ophthalmology

Therapeutic Indications

Age-related macular degeneration

Founders

Ronjon NagDebasish Sinha

Website

https://www.ikshanatherapeutics.com/
Ikshana Therapeutics, Inc.

Ikshana Therapeutics is developing treatments for age-related disease, beginning with dry age-related macular degeneration. Its research aims to restore cellular maintenance processes that decline with age and contribute to retinal damage. The company's pipeline includes CRYBA1 gene therapy and a lipocalin-2 antibody program, bringing complementary approaches to protecting vision. [1] [2]

Led by Ronjon Nag and scientific co-founder Debasish Sinha, Ikshana connects life-sciences entrepreneurship with retinal biology and gene-therapy expertise. Sinha previously held an endowed ophthalmology research chair at the University of Pittsburgh, linking the company's work to Pitt's strength in vision research. [3]

Discover More with AI